918890-17-2

Upstream product

• 904913-97-9 [2-(2,6-difluorophenoxy)-5-nitro-pyrimidin-4-yl]-ethyl-amine 
• 330550-93-1 (2-chloro-5-nitro-pyrimidin-4-yl)-ethyl-amine 
• 28177-48-2 2,6-difluorophenol 

Downstream Products

• 946053-69-6 8-(2-chlorophenyl)-2-(2,6-difluorophenoxy)-9-ethyl-9H-purine 
• 904914-03-0 8-(2-chloro-phenylsulfanyl)-2-(2,6-difluoro-phenoxy)-9-ethyl-9H-purine 
• 904913-99-1 8-chloro-2-(2,6-difluoro-phenoxy)-9-ethyl-9H-purine 
• 918890-39-8 [2-(2,6-difluoro-phenoxy)-9-ethyl-9H-purin-8-yl]-(2-fluoro-phenyl)-methanol 
• 904914-14-3 (2-chloro-phenyl)-[2-(2,6-difluoro-phenoxy)-9-ethyl-9H-purin-8-yl]-methanol 
• 918890-25-2 2-(2,6-difluoro-phenoxy)-9-ethyl-7,9-dihydro-purin-8-one 

Relevant academic research and scientific papers

Purine cytokine inhibitors

The present invention relates to 2,8,9-substituted purines which inhibit the extracellular release of inflammatory cytokines, said cytokines responsible for one or more human or higher mammalian disease states. The present invention further relates to com

The development of novel C-2, C-8, and N-9 trisubstituted purines as inhibitors of TNF-α production

A series of C-2, C-8, and N-9 trisubstituted purine based inhibitors of TNF-α production are described. The most potent analogs showed low nanomolar activity against LPS-induced TNF-α production in a THP-1 cell based assay. The SAR of the series was optim